Literature DB >> 20092786

Optimal time for human umbilical cord blood cell transplantation in rats with myocardial infarction.

Yun-li Xing1, Lu-hua Shen, Hong-wei Li, Yu-chen Zhang, Lin Zhao, Shu-mei Zhao, Qing Xu.   

Abstract

BACKGROUND: Cell therapy for cardiac regeneration is still under investigation. To date there have been a limited number of studies describing the optimal time for cell injection. The present study aimed to examine the optimal time for human umbilical cord blood cells (HUCBCs) transplantation after myocardial infarction (MI).
METHODS: The animals underwent MI by ligation of the left anterior descending coronary artery and received an intravenous injection of equal volumes of HUCBCs or phosphate buffered saline at days 1, 5, 10 and 30 after MI. HUCBCs were detected by immunostaining against human human leucocyte antigen (HLA). Cardiac function, histological analysis and measurement of vascular endothelial growth factor (VEGF) were performed 4 weeks after cell transplantation.
RESULTS: HUCBCs transplantation could improve cardiac function in rats that received transplantation at 5 and 10 days after MI. The best benefit was achieved in rats that received cells at 10-day after MI. Survival of engrafted HUCBCs, angiogenesis and VEGF expression were more obvious in the 10-day transplantation group than in the other transplantation groups. No evidence of cardiomyocyte regeneration was detected in any transplanted rats.
CONCLUSIONS: HUCBCs transplantation could improve cardiac function in rats that received HUCBCs at days 5 and 10 after MI with the optimal time for transplantation being 10 days post MI. Angiogenesis, but not cardiomyocyte regeneration, played a key role in the cardiac function improvement.

Entities:  

Mesh:

Year:  2009        PMID: 20092786

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  4 in total

1.  Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction.

Authors:  Sandra A Acosta; Nick Franzese; Meaghan Staples; Nathan L Weinbren; Monica Babilonia; Jason Patel; Neil Merchant; Alejandra Jacotte Simancas; Adam Slakter; Mathew Caputo; Milan Patel; Giorgio Franyuti; Max H Franzblau; Lyanne Suarez; Chiara Gonzales-Portillo; Theo Diamandis; Kazutaka Shinozuka; Naoki Tajiri; Paul R Sanberg; Yuji Kaneko; Leslie W Miller; Cesar V Borlongan
Journal:  J Stem Cell Res Ther       Date:  2013-07-01

2.  Beneficial effects of non-matched allogeneic cord blood mononuclear cells upon patients with idiopathic osteoporosis.

Authors:  Jun Li; Li Zhang; Liang Zhou; Zheng-Ping Yu; Feng Qi; Bei Liu; Su-Xia Zi; Li Li; Yi Li; San-Bin Wang; Zheng-Jiang Cui; Xing-Hua Pan
Journal:  J Transl Med       Date:  2012-05-21       Impact factor: 5.531

3.  Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions.

Authors:  Wan-Zhang Yang; Yun Zhang; Fang Wu; Wei-Ping Min; Boris Minev; Min Zhang; Xiao-Ling Luo; Famela Ramos; Thomas E Ichim; Neil H Riordan; Xiang Hu
Journal:  J Transl Med       Date:  2010-08-03       Impact factor: 5.531

4.  Human umbilical cord blood-derived mononuclear cells improve murine ventricular function upon intramyocardial delivery in right ventricular chronic pressure overload.

Authors:  Saji Oommen; Satsuki Yamada; Susana Cantero Peral; Katherine A Campbell; Elizabeth S Bruinsma; Andre Terzic; Timothy J Nelson
Journal:  Stem Cell Res Ther       Date:  2015-03-26       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.